SCHEMBL8149192

SCHEMBL8149192

O=C(CBr)N1CCN(C(=O)CBr)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
KMT2A Q03164 4/20 0.62
HSD17B10 Q99714 2/20 0.62
MEN1 O00255 2/20 0.62
KDM4E B2RXH2 1/20 0.62
USP2 O75604 1/20 0.62
LMNA P02545 1/20 0.62
CYP3A4 P08684 1/20 0.62
HPGD P15428 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
GAA P10253 1/20 0.44
ATM Q13315 1/20 0.42
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
TRPA1 O75762 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27155224 1.00 ALDH1A1 (0.62) ALDH1A1KMT2AHSD17B10MEN1KDM4E
SCHEMBL21765685 0.92 ALDH1A1 (0.54) ALDH1A1KMT2AHSD17B10MEN1KDM4E
SCHEMBL2110436 0.89 ALDH1A1 (0.52) ALDH1A1KMT2AHSD17B10MEN1KDM4E
SCHEMBL1037993 0.88
SCHEMBL21765684 0.88 ALDH1A1 (0.50) ALDH1A1KMT2AHSD17B10MEN1KDM4E
SCHEMBL20129907 0.88
SCHEMBL4498918 0.87 TDP1 (0.52) ALDH1A1KMT2AHSD17B10MEN1KDM4E
SCHEMBL7469848 0.87 TDP1 (0.52) ALDH1A1KMT2AHSD17B10MEN1KDM4E
SCHEMBL772021 0.86 ATM (0.54) ALDH1A1KMT2AHSD17B10MEN1KDM4E
Hydrochloric Acid SCHEMBL7476884 0.85 TDP1 (0.50) ALDH1A1KMT2AHSD17B10MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210179665-A1 COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF PARABILIS MEDICINES, INC. 2021-06-17 US disclosed
WO-2020041270-A1 COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF FOG PHARMACEUTICALS, INC. (US) 2020-02-27 WO disclosed
WO-2015172171-A2 NOVEL ANTHRAQUINONE DERIVATIVES SEALIFE PHARMA GMBH (AT) 2015-11-19 WO disclosed
US-6041157-A Environmentally sensitive compositions of matter based on 3H-fluoren-3-ylidenes and process for making same GOETZ FREDERICK JAMES (US) 2000-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179665-A1 COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF IAPP, VIP, NGLY1 ALDH1A1 4780/4885KMT2A 4529/4885HSD17B10 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.